Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus Bevacizumab Versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-label, Phase 3, Randomised Controlled Trial. Lancet 2019;393:2404–15: Putting IMmotion into Motion: Personalizing Frontline Treatment for Metastatic Renal Cell Carcinoma

Publication date: Available online 30 October 2019Source: European UrologyAuthor(s): Nirmish Singla
Source: European Urology - Category: Urology & Nephrology Source Type: research